LAEKNA-B (02105) issues a total of 15,323,500 restricted stock units.
Kaixin Pharmaceuticals-B (02105) announced that on May 8, 2026, a total of 15,323,500 restricted stock units (equivalent to a total of 15,323,500 shares) were granted to grantees (including three executive directors) under the 2024 stock incentive plan. The grant of restricted stock units to the three executive directors, including Dr. Lv Xiangyang, Ms. Xie Ling, and Dr. Gu Xiangju, will only become effective after approval by independent shareholders at the annual general meeting.
LAEKNA-B (02105) announced on May 8, 2026 that a total of 15,323,500 restricted share units (equivalent to 15,323,500 shares) were granted to grantees (including three executive directors) in accordance with the 2024 share incentive plan. The grant of restricted share units to the three executive directors, including Dr. Lu Xiangyang, Ms. Xie Ling, and Dr. Gu Xiangju, is subject to approval by independent shareholders at the annual general meeting before it can be made effective.
Related Articles
LEADS BIOLABS-B(09887): China Securities Regulatory Commission issues filing notice for full circulation of H shares and company's plan to implement H share full circulation plan.
"Anti-vaccine warrior" Kennedy "takes on" Merck & Co., Inc. (MRK.US) in a courtroom showdown over the billion-dollar business of the Gardasil vaccine.
New Stock News | Xinde Semiconductor Second Listing on Hong Kong Stock Exchange
LEADS BIOLABS-B(09887): China Securities Regulatory Commission issues filing notice for full circulation of H shares and company's plan to implement H share full circulation plan.
"Anti-vaccine warrior" Kennedy "takes on" Merck & Co., Inc. (MRK.US) in a courtroom showdown over the billion-dollar business of the Gardasil vaccine.
New Stock News | Xinde Semiconductor Second Listing on Hong Kong Stock Exchange
